We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us

VEDA LAB

VEDALAB focuses on the development, production and marketing of in vitro immunodiagnostic reagents and instruments. I... read more Featured Products: More products

Download Mobile App





VedaLab Showcases Comprehensive Portfolio for Rapid Diagnostic Testing

By LabMedica International staff writers
Posted on 18 Nov 2025

VEDALAB SA is presenting its comprehensive portfolio of rapid tests, immunodiagnostic reagents and point-of-care (POC) technologies at MEDICA 2025. More...

Exhibiting in Hall 1, Stand A64, the company is showcasing solutions designed for clinical laboratories, primary care settings, and supervised home testing.

VedaLab’s exhibitor profile at MEDICA 2026 highlights several key rapid test products: GLUTEN’ALARM is an immunochromatographic test for the qualitative detection of anti-tissue transglutaminase IgA antibodies associated with Gluten intolerance (celiac disease) in whole blood. STREPA’ALERT provides rapid detection of Group A Streptococcus from throat swabs for clinical and near patient use. Babycheck 1 WB, a whole blood pregnancy test, reflects the company’s experience in CE marked home use diagnostics. Additional highlighted products include URICHECK for rapid uric acid screening and VedaLab’s latex reagent line for routine serological and immunological applications.

Another major feature at the company’s booth is the EASY READER+ instrument. This POC device enables quantitative measurements from finger-prick whole blood samples using lateral flow rapid tests. The instrument includes a touchscreen interface, enhanced memory and internet-based upgrading. EASY READER+ and its associated quantitative tests are designed for use in physician offices, clinical laboratories and online pharmacy networks, as well as supervised consumer testing through diagnostic information providers.

Laboratory professionals, point-of-care coordinators and distribution partners attending MEDICA 2025 can visit Hall 1, Stand A64 to discover VedaLab's latest self-testing innovations and explore our full panel of solutions.

Related Links:
VedaLab


New
Gold Member
Automatic Hematology Analyzer
CF9600
Gold Member
Quality Control Material
iPLEX Pro Exome QC Panel
New
HIV-1 Molecular Diagnostic Assay
AltoStar HIV RT-PCR Kit 1.5
New
Chromogenic Culture System
InTray™ COLOREX™ ECC
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Molecular Diagnostics

view channel
Image: The portable platform could address diagnostic gaps for tuberculosis testing in clinics without access to advanced laboratory infrastructure (photo credit: Shutterstock)

Portable Test Detects Tuberculosis from Tongue Swabs in 30 Minutes

Despite decades of effective drug regimens, tuberculosis remains the leading cause of death from an infectious disease, driven in part by limited access to accurate, rapid testing. Conventional diagnostics... Read more

Pathology

view channel
Image: The researchers derived a gene-based signature and a blood test to help identify this high-risk subgroup (photo credit: Shutterstock)

New Tissue Mapping Approach Identifies High-Risk Form of Diabetic Kidney Disease

Diabetic kidney disease is a leading cause of chronic kidney disease and end-stage kidney disease, affecting 20%–40% of people with diabetes and more than 107 million individuals worldwide as of 2021.... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.